CA3247422A1 - IMMUNE CELL INHIBITION BY IMMUNE CHECKPOINT ENGAGERS - Google Patents

IMMUNE CELL INHIBITION BY IMMUNE CHECKPOINT ENGAGERS

Info

Publication number
CA3247422A1
CA3247422A1 CA3247422A CA3247422A CA3247422A1 CA 3247422 A1 CA3247422 A1 CA 3247422A1 CA 3247422 A CA3247422 A CA 3247422A CA 3247422 A CA3247422 A CA 3247422A CA 3247422 A1 CA3247422 A1 CA 3247422A1
Authority
CA
Canada
Prior art keywords
cell
cells
ice
engager
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3247422A
Other languages
English (en)
French (fr)
Inventor
Tobias Deuse
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of CA3247422A1 publication Critical patent/CA3247422A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/36—Immune checkpoint inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
CA3247422A 2022-04-13 2023-04-11 IMMUNE CELL INHIBITION BY IMMUNE CHECKPOINT ENGAGERS Pending CA3247422A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263330539P 2022-04-13 2022-04-13
US63/330,539 2022-04-13
US202363448081P 2023-02-24 2023-02-24
US63/448,081 2023-02-24
PCT/US2023/018189 WO2023200796A1 (en) 2022-04-13 2023-04-11 Immune cell inhibition by immune checkpoint engagers

Publications (1)

Publication Number Publication Date
CA3247422A1 true CA3247422A1 (en) 2023-10-19

Family

ID=88330149

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3247422A Pending CA3247422A1 (en) 2022-04-13 2023-04-11 IMMUNE CELL INHIBITION BY IMMUNE CHECKPOINT ENGAGERS

Country Status (7)

Country Link
US (1) US20250268949A1 (https=)
EP (1) EP4507727A4 (https=)
JP (1) JP2025513879A (https=)
CN (1) CN119183385A (https=)
AU (1) AU2023251864A1 (https=)
CA (1) CA3247422A1 (https=)
WO (1) WO2023200796A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024177982A2 (en) * 2023-02-24 2024-08-29 The Regents Of The University Of California Lilrb1 engager cells
WO2025098508A1 (zh) * 2023-11-10 2025-05-15 贝达药业股份有限公司 标记性多肽、治疗剂及其应用
WO2025166550A1 (zh) * 2024-02-06 2025-08-14 香港北恒生物科技有限公司 工程化细胞及其用途
CN117903311B (zh) * 2024-03-20 2024-10-25 湖南卓润生物科技有限公司 sST2特异性结合蛋白及其制备方法和应用
CN120340611B (zh) * 2025-04-02 2025-09-23 中瑞德泰生物科技集团有限公司 Car-nk细胞数据的特征提取方法及系统

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2488876A1 (en) * 2002-06-13 2003-12-24 Oregon Health & Science University Activating mutations of platelet derived growth factor receptor alpha (pdgfra) as diagnostic markers and therapeutic targets
US20180133327A1 (en) * 2015-03-16 2018-05-17 Amal Therapeutics Sa Cell Penetrating Peptides and Complexes Comprising the Same
JP2020506943A (ja) * 2017-02-07 2020-03-05 メモリアル スローン ケタリング キャンサー センター 養子免疫療法における抗原特異的ｔ細胞と組み合わせた免疫チェックポイント調節剤の使用
KR102777151B1 (ko) * 2017-11-21 2025-03-05 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 인터루킨-2의 부분 효능제
AR114127A1 (es) * 2018-03-02 2020-07-22 Lilly Co Eli Anticuerpos agonistas contra pd-1 y usos de estos
US11840575B2 (en) * 2019-05-07 2023-12-12 Gracell Biotechnologies (Shanghai) Co., Ltd. Engineered immune cells targeting BCMA and their uses thereof

Also Published As

Publication number Publication date
JP2025513879A (ja) 2025-04-30
EP4507727A1 (en) 2025-02-19
WO2023200796A1 (en) 2023-10-19
EP4507727A4 (en) 2026-04-08
AU2023251864A1 (en) 2024-10-03
US20250268949A1 (en) 2025-08-28
CN119183385A (zh) 2024-12-24

Similar Documents

Publication Publication Date Title
US20240043803A1 (en) Innate immune cell silencing by sirp-alpha engager
US20250268949A1 (en) Immune cell inhibition by immune checkpoint engagers
AU2018388413B2 (en) Enhanced immune effector cells and use thereof
CN111247242B (zh) 嵌合抗原受体(CARs)、组合物及其使用方法
WO2021173985A2 (en) Methods of making chimeric antigen receptor-expressing cells
JP2022513040A (ja) コンパートメント特異的カーゴ送達のための組成物および方法
KR20250084985A (ko) 조작된 면역 효과기 세포 및 이의 용도
US20180000914A1 (en) Anti-hsp70 specific chimeric antigen receptors (cars) for cancer immunotherapy
US20250152717A1 (en) Binding proteins and engineered cells specific for neoantigens and uses thereof
IL301983A (en) Transgenic induced pluripotent stem cells and effector carrier cells of the immune system
JP2024531234A (ja) 同種異系細胞療法のための遺伝子改変された初代細胞
JP2024534772A (ja) 同種異系細胞療法用の遺伝子改変細胞
WO2024046394A1 (zh) 增强受体、表达增强受体的免疫细胞及其用途
JP2024526237A (ja) 同種異系養子細胞療法のための保護されたエフェクター細胞及びその使用
US20250032544A1 (en) Sirpalpha switch receptors
WO2024177975A2 (en) Tim3 engager cells
WO2024177982A2 (en) Lilrb1 engager cells
WO2024177978A1 (en) Lilrb3 engager cells
US20250230470A1 (en) Safety switches to control in vitro and in vivo proliferation of cell therapy products
US20250388646A1 (en) Enhancing effector cell durability and efficacy in adoptive cell therapies
WO2026072856A2 (en) Comprehensively immune protected cells
WO2025054202A1 (en) Method of screening a sample comprising a transgene with a unique barcode
WO2024097800A1 (en) Off-the-shelf therapeutic cells with multiplex genomic engineering for targeting kallikrein-2
WO2024097901A1 (en) Off-the-shelf therapeutic cells with multiplex genomic engineering for targeting cd79b
CN118434844A (zh) 用于减少补体介导的炎症反应的同种异体细胞疗法的基因修饰的细胞

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20241002

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED

Effective date: 20241002

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W200 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST OR RESPONSE SUBMITTED ONLINE

Effective date: 20241002

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241002

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241022

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241022

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REGISTER A DOCUMENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241022

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20241115

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS

Effective date: 20241115

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20241119

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250404

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250404